Hanmi Financial Launches Aditams: Innovative Urological Treatment in Mexico

Hanmi Pharmaceutical Expands Innovative Urological Treatments in Mexico

Hanmi Pharmaceutical has officially launched its pioneering urological product, Aditams, in Mexico, marking a significant advancement in the treatment of Obstructive Prostatic Growth (OPG) and Erectile Dysfunction (ED). This launch represents the first export of a urological combination drug to Mexico, achieved through a strategic partnership with Laboratorios Silanes, a well-established Mexican pharmaceutical firm. The collaboration, which began with an export agreement in October 2020, sets the stage for Hanmi's continued expansion into the Latin American market. By combining tamsulosin and tadalafil into a single capsule through its proprietary Poly-Cap technology, Hanmi aims to provide a more effective treatment option for patients dealing with these common urological conditions.

The introduction of Aditams is particularly noteworthy as it builds on Hanmi's previous successes in the region. The company has already established a foothold in the Latin American pharmaceutical landscape with the launches of its products Lodarta and Bicartial-CTD in 2023 and 2024, respectively. These products have garnered positive reception, facilitated by Laboratorios Silanes' robust distribution network and industry expertise. As Hanmi Pharmaceutical expands its portfolio, Aditams represents a crucial step in addressing the pressing need for innovative treatments in Mexico, where the prevalence of OPG and ED is on the rise.

This launch is not only a testament to Hanmi's commitment to enhancing patient care but also highlights the company's strategy of leveraging local partnerships to navigate new markets. By aligning with Laboratorios Silanes, Hanmi not only benefits from their established presence but also reinforces its mission to improve healthcare outcomes through innovation. The successful debut of Aditams is expected to pave the way for further products and collaborations, as Hanmi continues to seek opportunities for growth and development in the competitive global pharmaceutical industry.

In addition to Aditams, Hanmi Pharmaceutical remains focused on expanding its research and development efforts to bring more innovative solutions to patients worldwide. The company's commitment to advancing healthcare is further underscored by its ongoing collaborations and its strategic approach to entering new markets. As the pharmaceutical landscape evolves, Hanmi's proactive initiatives ensure it remains at the forefront of providing effective treatments for pressing health concerns.

Overall, the launch of Aditams in Mexico signifies a crucial milestone for Hanmi Pharmaceutical, reinforcing its presence in Latin America while addressing the critical health issues of OPG and ED with an innovative product designed to improve the quality of life for patients.